Exploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 209
DOI: 10.1055/s-0044-1786596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von J Lazaro und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Resistance to blinatumomab (CD19-CD3 BiTE) is a significant obstacle in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), prompting the investigation of novel drug combinations. We aimed to generate an "in vitro" model capable of identifying synergistic combinations to enhance blinatumomab's efficacy in BCP-ALL treatment. Drug response profiling used annexin V/propidium iodide/CD3 staining and flow cytometry analysis in 28 patient samples and 4 cell lines. Co-cultured with healthy donor T-cells, samples were treated for 24h with blinatumomab and/or other inhibitors. Differential sensitivity to blinatumomab was observed among patient samples and cell lines. Idelalisib (tyrosin kinase inhibitor; TKi) combined with blinatumomab exhibited potential antagonistic effects. Birinapant (SMAC mimetic) and venetoclax (BCL2 inhibitor) demonstrated increased efficacy in BCP-ALL cell lines, displaying synergistic potential with blinatumomab. Our findings support TKi and SMAC mimetics' immunomodulatory effects, in accordance to prior anti-CD19 CAR T cell reports. Venetoclax emerges as a promising candidate for combination therapy against blinatumomab resistance. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Lazaro, J., Alcon, C., Lissat, A., Montero, J., & Eckert, C. (2024). Exploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia. Klinische Pädiatrie, 236(03), 209. https://doi.org/10.1055/s-0044-1786596
Vancouver
Lazaro J, Alcon C, Lissat A, Montero J, Eckert C. Exploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia. Klinische Pädiatrie. 2024;236(03):209. doi:10.1055/s-0044-1786596
BibTeX
@article{Lazaro2024,
author = {Lazaro, J and Alcon, C and Lissat, A and Montero, J and Eckert, C},
title = {Exploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {209},
doi = {10.1055/s-0044-1786596}
}
EUVIMED